WO1999013864A2 - Solid solution beadlet - Google Patents
Solid solution beadlet Download PDFInfo
- Publication number
- WO1999013864A2 WO1999013864A2 PCT/US1998/019658 US9819658W WO9913864A2 WO 1999013864 A2 WO1999013864 A2 WO 1999013864A2 US 9819658 W US9819658 W US 9819658W WO 9913864 A2 WO9913864 A2 WO 9913864A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- acyclovir
- beadlets
- therapeutic agent
- beadlet
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
Definitions
- the present invention relates to the field of pharmaceutical delivery formulations and, more particularly, to those providing rapid release of the therapeutic agent upon oral delivery.
- micropellets A variety of methods for forming micropellets are known in the art. See Kennedy and Niebergall, Development and Optimization of a Solid Dispersion Hot- Melt Fluid Bed Coating Method, Pharmaceutical Development and Technology, 1(1 ):51-62(1996); Hincal and Kas, Preparation of Micropellets by Spray Congealing, in Multiparticulate Oral Drug Delivery, Ghebre-Sellassie (Ed.), Marcel Dekker, Inc. NY, pgs. 17-34 (1994); Eldem et al., Polymorphic of Sprayed Lipid Micropellets and its Evaluation by Differential Scanning Calorimetry and Scanning Electron Microscopy, Pharmaceutical Research.
- a composition including at least one therapeutic agent and a pharmaceutically acceptable carrier in the form of a solid beadlet wherein the beadlet includes a combination of at least one hydrophobic long chain fatty acid or fatty acid ester and at least one surfactant.
- the hydrophobic long chain fatty acid or ester thereof and surfactant are present in the beadlet as a solid solution.
- the therapeutic agent is dispersed in the solid beadlet and is present in the composition in a therapeutically effective amount, with such amount generally being at least 0.001 %, by weight, of the composition.
- the hydrophobic long chain fatty acid or ester thereof is generally present in an amount of at least 20 % with such material in most cases being present in an amount no greater than 97%, by weight.
- the beadlet(s) generally has a particle size that does not exceed 1000 microns. In most cases, the particle size is at least 50 microns. In one embodiment, the particle size does not exceed 500 microns. In another embodiment, the particle size is from 100 to 350 microns.
- the surfactant is one that is liquid at room temperature in that a liquid surfactant in the composition of the invention provides for improved drug delivery.
- the surfactant may comprise at least 3 % of the core beadlet formulation and in many cases exceeds 10%of the core beadlet formulation all by weight.
- the beadlet is preferably in the form of a solid solution wherein the therapeutic agent is dissolved in the hydrophobic material.
- the invention provides a solid solution beadlet (used synonymously with granule or particle) comprising (i) at least about 20% by weight of a hydrophobic long chain fatty acid or ester material; (ii) from about 3% to about 40% by weight of a surfactant; and (iii) from about 1% to about 70% by weight of a therapeutic agent, which in admixture form a solid solution at room temperature.
- a solid solution beadlet used synonymously with granule or particle
- a solid solution beadlet comprising (i) at least about 20% by weight of a hydrophobic long chain fatty acid or ester material; (ii) from about 3% to about 40% by weight of a surfactant; and (iii) from about 1% to about 70% by weight of a therapeutic agent, which in admixture form a solid solution at room temperature.
- the long chain acids used as an acid or ester generally include at least 12 carbon atoms and generally do not include more than 22 carbon atoms.
- the acids may be saturated or unsaturated and generally are aliphatic long chain acids.
- the ester is preferably a glycerol ester.
- the ester may be a mono-, di or tri- ester of glycerol.
- the hydrophobic material is preferably oleic acid, gadoleic acid, eurcic acid, linoleic acid, linolenic acid, ucinoleic acid, riachidonic acid, glycerol esters of the foregoing acids, or glycerol behenate.
- the hydrophobic material preferably has a melting point of from about 40 to about 150°C, and is most preferably glyceryl behenate (e.g. CompritolTM from Gattefosse Inc., France).
- the surfactant is preferably selected from the group consisting of polyglycolyzed glycerides, polyoxyethylene sorbates. ethylene or propylene block copolymers or combinations thereof, and is most preferably polyoxyethylene 20 sorbitan monolaurate or Labrasol®, a polyglycohzed glyceride (Gattefosse, France).
- the beadlet can further include sodium C 9 -C 30 alkyl sulfate or citric acid.
- the beadlet can also contain a glidant (such as fumed silicon dioxide) to improve tabletting properties.
- a glidant such as fumed silicon dioxide
- preferred therapeutic agents include acyclovir, acyclovir and at least one additional antiviral agent, dihydroergotamine or methylphenidate.
- the beadlets are coated with an immediate release coating, such as Opadry®I (hydropropylmethylcellulose. i.e.. HPMC) and Opadry®-II (HPMC, maltodextrin and propyleneglycol) from Colorcon, Inc. (West Point, PA) or Aquateric® (cellulose acetate phthalate enteric polymer) from FMC, Inc. (Philadelphia, PA).
- Opadry®I hydropropylmethylcellulose. i.e.. HPMC
- Opadry®-II HPMC, maltodextrin and propyleneglycol
- Aquateric® cellulose acetate phthalate enteric polymer
- compositions of a plurality of coated or uncoated single phase solid solution beadlets in a pharmaceutically acceptable carrier can be, for example, in the form of a tablet (optionally coated, such as with an enteric coating), buccal tablet, sublingual tablet, capsule or other oral dose delivery forms.
- the oral deliver)' form can also be coated, if desired, with various protective coating materials or with materials that control the rate or location of release in the patient. This can be done by known methods using such known materials.
- Figure 1 is a plot of acyclovir transport through a Caco-2 cell monolayer using several of the Formulations described in Example 1.
- Figure 2 is a plot of acyclovir-containing beadlet percent dissolution over time for two of the Formulations from Example 1. It illustrates the immediate release acyclovir dissolved (%) over time from beadlets containing high percentages of glyceryl behenate and Labrasol®.
- Figure 3 is a plot of acyclovir-containing beadlet percent dissolution over time for two of the Formulations from Example 1. It illustrates the effect of different methods of preparing acyclovir-beadlets, i.e. spray-melt and spray congealing on acyclovir release.
- Figure 4 is a plot of acyclovir transport through a Caco-2 cell monolayer using Formulations of Example 2. Spray congealed acyclovir-containing beadlets are compared with control and placebo.
- Figure 5 is a plot of acyclovir transport through a Caco-2 cell monolayer using Formulations of Example 2.
- Peptiscreen® results of acyclovir from beadlets made by a variety of processes are presented. Beadlets of Formulation PD0030-40 has an optional coating applied.
- Figure 6 is a plot of acyclovir-containing beadlet percent dissolution over time for two of the Formulations from Example 2. It illustrates dissolution results from coated acyclovir beadlets (Formulation PD0030-40) made by a hot melt granulation process and uncoated acyclovir beadlets (Formulation PD0030-49) made by a spray congealing method.
- Figure 7 is a plot of acyclovir-containing beadlet percent dissolution over time for two of the Formulations from Example 2. It illustrates dissolution results from acyclovir beadlets made by a spray melt process (Formulation PD0030-52) and a hot melt process (Formulation PD0030-54). Both procedures give immediate release beadlets containing 48% glyceryl behenate.
- Figure 8 is a plot of acyclovir-containing beadlet percent dissolution over time for one of the Formulations of Example 3.
- Figure 9 is a plot of acyclovir transport through a Caco-2 cell monolayer using several of the Formulations described in Example 3.
- Peptiscreen® results of acyclovir transport from beadlets made by either spray congealing or hot melt granulation containing an anti-attacking agent are presented. Coated and uncoated beadlets are compared to the control.
- Figure 10 is a plot of acyclovir-containing beadlet percent dissolutions over time for two of the Formulations from Example 3. It illustrates dissolution of acyclovir-containing hot melt beadlets, comparing Opadry coated beadlets with uncoated beadlets.
- Figure 11 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from Example 4. It illustrates dissolution results from acyclovir tablets containing coated beadlets made by the hot melt granulation process.
- Figure 12 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from Example 4. It illustrates the difference between tablets that contain Ac-Di-Sol® (Formulation PD0029-41B) and those that do not contain Ac-Di-Sol® (Formulation PD0029-41C) a rapid disintegrant.
- Figure 13 is a plot of acyclovir transport through a Caco-2 cell monolayer using several formulations from Example 4. Peptiscreen® results of acyclovir transport from beadlets made by hot-melt granulation containing various percentages of Compritrol 888 ATO and acyclovir are presented.
- Figure 14 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from Example 5. These are 100 mg acyclovir tablets containing Labrasol® beadlets with an Opadry® coating.
- Figure 15 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from Example 5 containing different tabletting excipients.
- Figure 16 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from Example 5. It illustrates the effect of different tabletting excipients on dissolution of acyclovir tablets containing coated beadlets.
- Figure 17 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from Example 5. It illustrates dissolution results from 100 mg acyclovir tablets containing coated beadlets blended with various tabletting lubricants.
- Figure 18 is a plot of acyclovir-containing tablet percent dissolution over time for the Formulation PD0033-55 from Example 6.
- Figure 19 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from Example 7.
- Figure 20 shows drug transport across Caco-2 cells from acyclovir beadlet formulation shown in Example 8.
- the beadlets were prepared by a spray-congealed method.
- the delivery system of the invention can be used to provide rapid controlled release of any of a broad variety of therapeutically active agents.
- cough suppressants such as dextromethorphan hydrobromide and codeine
- antibiotics such as cephalosporin
- antihistamines such as chlorpheniramine maleate, brompheniramine maleate, loratidine, astemizole, diclofenac sodium and terfenadine
- decongestants such as pseudoephedrine and phenylephrine
- antihypertensives such as ACE-inhibitors, verapamil, nifedipine, propanolol, metoprolol, metoprolol succinate, metoprolol fumarate, metoprolol, methylphenadate, tartarate
- agents to treat attention deficit disorder/hyperactivity such as methylphenadate, d and or 1 isomers of methylphenadate, amphetamines, d and/or 1 is
- anti-Parkinson agents such as selegiline, carbidopa/levodopa, pergolide, bromocriptine, amantadine, trihexyphenidyl HCl
- antiviral agents including antiherpesvirus agents such as acyclovir, famciclovir, valcyclovir, foscarnet, ganciclovir
- antiretroviral agents such as didanosine, stavudine, zalcitabine, zidovudine
- anti Alzheimer's agents such as galantamine
- other therapeutic agents such as cimetidine, propiomazine, phenytoin, tacrine, propiazam, proplazam; vinca alkaloid.
- therapeutic polypeptides and proteins including fragments, analogs and mimetics thereof, and prodrugs which possess the same therapeutic activity, to at least a therapeutically useful extent, such as vasopressin, desmopressin, LHRH, luprolide, buserelin, calcitonin, insulin, parathyroid hormone, growth hormone(s) and erythropoietin.
- examples include cyclosporin, angiotensin I, II and III, encephalins, enkephalins and their analogs, ACTH, antiinflammatory peptides I, II, III, bradykinin, cholecystikinin (CCK) fragments 26-33 and 30-33, pre/pro CCK (V-9-M), ⁇ -endorphin, dinorphin, leucokinin, leutinizing hormone releasing hormone (LHRH), neurokinins (e.g., neurokinin A), somatostatin, substance P, thyroid releasing hormone (TRH), vasopressin, fibrinogen receptor antagonists (arginine-glycine-aspartic acid containing peptides) which are platelet aggregation antagonists or inhibitors, growth hormone releasing peptides (GHRP), o
- GPIIb/IIIa receptor blockers such as the prodrug orbofiban, atrial natreutetic factor, gastrin, cytoprotectives, MSH modulators, or elastase or growth factors and cytokines, renin inhibitors, and HIV protease inhibitors.
- Therapeutic agents can also include immunoactive agents selected from peptides, proteins, glycopolysaccharides and glycoproteins and fragments and analogs thereof, which possess the ability to suppress or eliminate immune responses thereto.
- Active analogs include compounds which have at least 90% structural homology to the proteins or to the active fragments.
- the term includes, without limitations, any combination of their polypeptide domains or fragments possessing the ability to eliminate or suppress immune responses to the protein upon oral administration such as is used for replacement therapy.
- polypeptides include hormones, such as insulin; polypeptides to supplement a deficiency in production of a physiologically important polypeptide, such as hematologic regulatory factor; or cell or tissue preparations such as allogeneic or xenogeneic tissue or cells.
- Therapeutic agents can also include immunoactive agents that can suppress or eliminate an immune response against allergens, particularly in cases of hypersensitivity caused by allergens, e *.
- Type IV cell-mediated (delayed type) hypersensitivity are also included.
- vaccines especially those yielding mucosal immunity.
- Therapeutic agents can also include those intended to be locally active in the gastrointestinal tract, such as therapeutics intended to treat Inflammatory Bowel Disease or Krohn's Disease, including corticosteroids such as beclomethasome dipropionate, budesonide, ffunisolide, cromolyn, and nedocromil sodium.
- corticosteroids such as beclomethasome dipropionate, budesonide, ffunisolide, cromolyn, and nedocromil sodium.
- the spray-congealing method begins with melting a typical pharmaceutically acceptible long chain alkyl-based wax that has a melting point of greater than or equal to about 55°C.
- Examples include stearic acid wax, glyceryl fatty acid esters (e.g. Compritol® brand), glyceryl monostearate or lauric acid wax.
- the melted wax is then mixed in a suitable mixing vessel, with the active pharmaceutical agent (usually 50-100 microns) and all other components of the beadlet composition, except for flow aids as described below.
- the mixture is sprayed into a spray-congeal tower or fluid bed processor.
- a flow of cool air is passed through the tower to solidify the beadlets.
- flow aids are added to prevent beadlet sticking, i.e. to make the beadlet surfaces more slippery, resulting in finished uncoated beadlets prepared by this method.
- the hot-melt method is performed in a fluid bed, which takes the form of a vertical cylinder resting in a bowl-shaped base (one such device used in the Examples is the Wurster inserted in a Glatt GPCG5 fluid bed).
- the side walls of the cylinders have a number of spray nozzle entry ports along their length.
- a dry powder paniculate mixture of the beadlet components, except for the wax and lubricant(s) is placed in the bowl and a metered flow of air is introduced into the cylinder. This raises the powder particles into the cylinder forcing a controlled flow pattern of the powder particles within at least one portion of the height of the cylinder.
- top spray melted wax and lubricant are introduced through some of these same nozzles, particularly the upper nozzles in an embodiment called the “top spray” method.
- the lower nozzles continue to introduce cool air from below to effect solidification of beadlets containing the powder, wax and lubricant components.
- the "top spray” method is used in several of the Examples presented herein.
- the spray-melt method is also performed in a fluid bed.
- Solid ingredients including wax that is solid at room temperature
- liquid surfactants or solubilizing agents are placed in a suitably configured fluid bed.
- Liquid surfactants, mixtures thereof and or solubilizing agents are then sprayed onto the solid ingredients already in the fluid bed. This results in particles which are actually separate but attached drug, wax and surfactant components. These separate-component particles are heated sufficiently to soften the wax, resulting in homogeneous particles which are then cooled to result in solidified beadlets.
- Several formulations in the Examples were prepared this way.
- composition or preparation of the invention can further include a surfactant, or a mixture of two or more surfactants.
- a surfactant is an amphiphilic molecule consisting of a hydrophobic tail and a hydrophilic head. These molecules possess distinct regions of both hydrophilic and hydrophobic character.
- the hydrophobic tail can be a hydrocarbon or fluorocarbon chain of 8 to 18 carbon atoms. They are long chain molecules such as, for example, soaps or detergents.
- Surfactants accumulate at the hydrophilic/ hydrophobic (water/oil) interface and lower the surface tension at the interface. One effect of a reduced surface tension is the stabilization of the emulsions.
- hydrophobic composition or other component of the preparation includes a surface- active agent, such as a surfactant, it is usually present in amounts of about 3% to 50.0% weight/weight of the beadlet or granule composition with a preferred range of 3% to 10%) (w/w).
- Preferred surfactants include, for example, the Tween (polyoxyethylene sorbate) family of surfactants (ICI, Wilmington, DE), the Span (sorbitan long chain carboxylic acid esters) family of surfactants (ICI), the Pluronic (ethylene or propylene oxide block copolymers) family of surfactants (BASF, Parsippany, NJ), the Labrasol, Labrafil and Labrafac (each polyglycolyzed glycerides) families of surfactants (GatteFosse, St.
- sorbitan esters of oleate, stearate, laurate or other long chain carboxylic acids poloxamers (polyethylene-polypropylene glycol block copolymers), other sorbitan or sucrose long chain carboxylic acid esters, mono and diglycerides, PEG derivatives of caprylic/capric acid triglycerides and mixtures thereof.
- Coating of the beadlets formed by any of the above methods is achieved as follows.
- Representative preferred surfactants are poloymer 124, a poly-glycolized glyceride, sorbitan laurate, polyoxyethlyene (20) sorbitan monooleate.
- An aqueous solution of an "immediate release" coating is formed and sprayed onto the beadlets substantially immediately after they have been formed, using the same apparatus and same nozzles by which the beadlets were formed.
- a list (non-limiting) of release coating materials and suppliers is provided in Table 1 below. At this point, more flow aid may be introduced briefly.
- the beadlets are then discharged to a blender (such as a Patterson-Kelly V-blender).
- Aeromatic and Multiprocessor series (Niro Inc., Columbia, MD 21045); GPCG series (Glatt Air Techniques, Inc., Ramsey, NJ 07446); Vector fluid bed series (Vector Corporation, Marion, IA 52302); and Kugel Coater series (Huttlin. Coating-Technik GmbH, Steinen, Germany).
- the beadlets can be incorporated into hard gelatin capsules, either with additional excipients, or alone.
- Typical excipients to be added to a capsule formulation include, but are not limited to: fillers such as microcrystalhne cellulose, soy polysaccharides, calcium phosphate dihydrate, calcium sulfate, lactose, sucrose, sorbitol, or any other inert filler.
- fillers such as microcrystalhne cellulose, soy polysaccharides, calcium phosphate dihydrate, calcium sulfate, lactose, sucrose, sorbitol, or any other inert filler.
- there can be flow aids such as fumed silicon dioxide, silica gel, magnesium stearate, calcium stearate or any other material imparting flow to powders. Because of their hydrophobic nature, the particles should not need a lubricant, but one can be added if necessary by using polyethylene glycol, leucine, glyceryl be
- the beadlets can also be incorporated into a tablet, in particular by incorporation into a tablet matrix, which rapidly disperses the particles after ingestion.
- a filler/binder In order to incorporate these particles into such a tablet, a filler/binder must be added to a tablet that can accept the particles, but will not allow their destruction during the tableting process.
- Materials that are suitable for this purpose include, but are not limited to, microcrystalline cellulose (Avicel), soy polysaccharide (Emcosoy), pregelatinized starches (STARCH 1500, National 1551), and polyethylene glycols (Carbowax). The materials should be present in the range of 5-75% (w/w), with a preferred range of 25-50% (w/w).
- disintegrants are added in order to disperse the particles once the tablet is ingested.
- Suitable disintegrants include, but are not limited to: cross-linked sodium carboxymethyl cellulose (Ac-Di-Sol), sodium starch glycolate (Explotab, Primojel), and cross-linked polyvinylpolypyrrolidone (Plasdone-XL) These materials should be present in the range of 3-15% (w/W), with a preferred range of 5-10% (w/w).
- Lubricants are also added to assure proper tableting, and these can include, but are not limited to: magnesium stearate, calcium stearate, stearic acid, polyethylene glycol, leucine, glyceryl behanate, and hydrogenated vegetable oil. These lubricants should be present in amounts from 0.1-10% (w/w), with a preferred range of 0.3-3.0%)
- Tablets are formed, for example, as follows.
- the particles are introduced into a blender along with Avicel, disintegrants and lubricant, mixed for a set number of minutes to provide a homogeneous blend which is then put in the hopper of a tablet press with which tablets are compressed.
- the compression force used is adequate to form a tablet; however, not sufficient to fracture the beads or coatings.
- the tablets can also be coated with conventional coatings known for a variety of effects, e.g. enteric, immediate or sustained release.
- the Caco-2 cell line is derived from human colon cancer cells. They are epithelial-type cells that differentiate, in culture, into cell monolayers that are extremely similar to normal fetal intestinal epithelium. Intestinal epithelium is the cell type that lines the intestine. It has very specific adsorptive and barrier properties to allow absorption of nutrients but prevent passage of most of the intestinal contents. Two important characteristics of intestinal epithelium are the brush border, which forms the luminal surface of the epithelium, and the tight junctions, which are impenetrable fusions between cells.
- the brush border is important because it produces the enzymes and specialized membrane structures that allow cells to selectively absorb important nutrients such as glucose; tight junctions are important because they form continuous connection between cells and allow the epithelium to exclude unwanted molecules.
- Caco-2 cells as used in our assays, display both of these characteristics.
- Caco-2 colon carcinoma cells were obtained from the American Tissue Culture Collection (Rockville, MD) and maintained in culture in high glucose DMEM with 10%) fetal calf serum, plus pen/strep, at 37°C, in 5% C0 2 . Cells are subcultured roughly every 5-7 days, 1 :3 in T75 flasks, or when cells are 80-90% confluent, as determined by visual inspection. Caco-2 cells are adherent and are disassociated from the surface of the flask by incubation at room temperature with 0.25% trypsin in Hank's balanced salt solution (HBSS) without calcium or magnesium. Caco-2 cells are contact inhibited and when they become confluent, begin to differentiate and lose the capacity to undergo mitosis.
- HBSS Hank's balanced salt solution
- Tissue culture reagents can be purchased from GIBCO-Life Technologies (Gaithersburg, MD) or Biofluids (Rockville, MD).
- TRH thyrotrophin releasing hormone
- TRH thyrotrophin releasing hormone
- Glucose transport is also measured using H and l4 C labeled D- and L- glucose.
- Unlabeled peptides can be purchased from Peninsula Laboratories, Belmont, CA.
- unlabeled peptides concentration 10 mM, and labeled, concentation of 1 ⁇ Ci per ml and transport enhancers, are added to HBSS plus calcium and magnesium.
- Transport media containing peptide or glucose plus labeled and unlabeled PEG, is added to the upper compartment of the Transwell, where the test solution is in contact with the apical surface of the cells. Transport is measured by taking aliquots from the lower compartment, which is in contact with the basal surface of the cells. Studies are performed in a six-well tissue culture plate and Transwells are moved to a new well every twenty minutes, giving determinations for two hours.
- Uncoated beadlets were prepared, as described above and in Table 2, to have the formulations set forth in Table 2.
- Table 2 demonstrates that acyclovir beadlets can be prepared by a variety of methods. Acyclovir, USP or micronized acyclovir can be used. The particle size of original drug does not affect the beadlet formation.
- Figure 2 is a plot of acyclovir-containing beadlet percent dissolution over time for two of the Formulations from this Example (PD0030-01A and PD0030-01D). It illustrates the immediate release acyclovir dissolved (%) over time from beadlets containing high percentages of glyceryl behenate and Labrasol®.
- Figure 3 is a plot of acyclovir-containing beadlet percent dissolution over time for two of the Formulations from this Example (PD0030-11 and PD0030-17). It illustrates the effect of different methods of preparing acyclovir-beadlets, i.e. spray-melt and spray congealing on acyclovir release.
- Example 2 Coated and Uncoated Beadlet Formulations Additional Formulations for coated and uncoated beadlets are provided in this Example. Preparation was as described above and in Tables 5 and 6.
- PD0030-52 and PD0030-54 illustrate beadlets made in a fluid bed processor with a Wurster inserter, used for either a spray-melt or a hot-melt granulation method.
- PD0030- 47 and PD0030-55 illustrate that spray-congealed beadlets can be coated with an enteric polymer (Eudragit L30D) at a 10% coating level and a 50% coating level, respectively.
- PD0030-63 is a placebo formulation.
- Figure 4 is a plot of acyclovir transport through a Caco-2 cell monolayer using Formulations of this Example. Spray congealed acyclovir-containing beadlets are compared with control and placebo.
- Figure 5 is a plot of acyclovir transport through a Caco-2 cell monolayer using Formulations of this Example.
- Peptiscreen® results of acyclovir from beadlets made by a variety of processes are presented. Beadlets of Formulation PD0030-40 have an optional coating applied.
- Figure 6 is a plot of acyclovir-containing beadlet percent dissolution over time for two of the Formulations from this Example. It illustrates dissolution results from coated acyclovir beadlets (Formulation PD0030-40) made by a hot melt granulation process and uncoated acyclovir beadlets (Formulation PD0030-49) made by a spray congealing method.
- Figure 7 is a plot of acyclovir-containing beadlet percent dissolution over time for two of the Formulations from this Example. It illustrates dissolution results from acyclovir beadlets made by a spray melt process (Formulation PD0030-52) and a hot melt process (Formulation PD0030-54). Both procedures give immediate release beadlets containing 48% glyceryl behenate.
- Figure 8 is a plot of acyclovir-containing beadlet percent dissolution over time for one of the Formulations of this Example (Formulation PD0030-69).
- Table 9 Beadlet Formulations
- PD0030-90 illustrates that beadlets can be coated with a Opadry® polymer solution using a conventional fluid bed processor.
- Table 1 1 shows that Acyclovir beadlets can be coated with opadry polymer individually, regardless of preparation methods, e.g., hot-melt or spray-congealing.
- Figure 9 is a plot of acyclovir transport through a Caco-2 cell monolayer using several of the Formulations described in this Example.
- Peptiscreen® results of acyclovir transport from beadlets made by either spray congealing or hot melt granulation containing an anti-attacking agent are presented. Coated and uncoated beadlets are compared to the control.
- Figure 10 is a plot of acyclovir-containing beadlet percent dissolutions over time for two of the Formulations from this Example. It illustrates dissolution of acyclovir- containing hot melt beadlets, comparing Opadry® coated beadlets with uncoated beadlets.
- Formulations PD0029-44A and -44B illustrate the addition of lubricant to tablet preparations. The tablets were studied for the effect of this on drug release.
- Formulations PD0029-45A through -45C illustrate the addition of starch 1500 to tablet preparations. The tablets were studied for the effect of this on drug release. Table 16 Beadlet Tablet Formulations
- PD0033-07A through -07C, PD0033-09A through -09C and PD0O33-11A through -11C were prepared to study the effect of transport enhancer on processing and drug transport a Caco 2 cell monolayer.
- the Labrasol® content was also modified to cover the range from 7.6% to 20%.
- PD33-13A through -13C show different amounts of transport enhancers to study their effect on processing and drug transport.
- Formulation PD0033-15 shows coating of a beadlet formed by hot-melt granulation with Opadry® II.
- Table 19 Acyclovir Transport Through Caco-2 Cell Monolayers
- Figure 11 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from this Example. It illustrates dissolution results from acyclovir tablets containing coated beadlets made by the hot melt granulation process.
- Figure 12 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from this Example. It illustrates the difference between tablets that contain Ac-Di-Sol® (Formulation PD0029-41B) and those that do not contain Ac-Di- Sol® (Formulation PD0029-41C) a rapid disintegrant.
- FIG. 13 is a plot of acyclovir transport through a Caco-2 cell monolayer using several formulations from this Example.
- Peptiscreen® results of acyclovir transport from beadlets made by hot-melt granulation containing various percentages of Compritrol 888 ATO and acyclovir are presented. The data are in tabular form in Table 19.
- Figure 14 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from this Example. These are 100 mg acyclovir tablets containing Labrasol® beadlets with an Opadry® coating.
- Figure 15 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from this Example containing different tabletting excipients.
- Figure 16 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from this Example. It illustrates the effect of different tabletting excipients on dissolution of acyclovir tablets containing coated beadlets. See Tables 20 and 21.
- Figure 17 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from this Example. It illustrates dissolution results from 100 mg acyclovir tablets containing coated beadlets blended with various tabletting lubricants. As much as 6% sodium stearoyl fiimarate is used in Formulation PD0029-56A, with loss in immediate release properties. See Table 21.
- Figure 18 is a plot of acyclovir-containing tablet percent dissolution over time for the Formulation PD0033-55 from this Example. Ii. presents dissolution results from 100 mg acyclovir tablets containing coated beadlets. The coated beadlets contain 60%> acyclovir and are Tween 20 based. Example 7 Table 23
- Figure 19 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from this Example. It presents dissolution results for 150 mg enteric coated acyclovir tablets containing coated beadlets made using either Tween 20 to Labrasol® surfactants in combination with 27% Compritrol 888 ATO.
- the acyclovir beadlets were prepared by a spray-congealed method.
- the stearic acid or Myvaplex 600 was melted in a stainless steel vessel.
- the other ingredients, except acyclovir powder, were then added into the molten solution of the wax while stirring.
- acyclovir was dispersed into the above molten solution at the temperature above the melting point of the mixture.
- the molten dispersion was pumped to a portable spray-dryer unit and atomized by a dual-fluid nozzle.
- the congealed product was collected either on the bottom of the chamber or in the cyclone.
- Figure 20 shows levels of drug transport in the Caco-2 cell model of the above prepared beadlets. Both the PD0022-37 formulation with Myvaplex 600 and the PD0022-38 formulation continuing stearic acid provided enhanced drug transport levels over the control.
- the following formulation was used to prepare amphetamine granules.
- the drugs and other ingredients were charged into a fluid bed processor (GPCG-5, Glatt).
- the molten components (Myvaplex 600 and Tween 20) were sprayed onto the fluidized powder bed under suitable conditions.
- the resulting granules were then coated with Opadry II.
- the drug-loaded granules can be further coated with enteric polymers or sustained release polymers.
- the final dosage form for the granules can be a capsule or a tablet. Table 25
- Formulations A and D The spray-melt method is performed in a fluid bed. Solid ingredients including the active ingredients, lactose Compritol 888 ATO, Myvaplex 600, SLS, and citric acid, are placed in a suitably configured fluid bed. Liquid surfactants, i.e., Tween 20 and Labrasol, are then sprayed onto the solid ingredients in the fluid bed to form granules. In the case of calcitonin sodium, lactose triturate is prepared to ensure content uniformity.
- Liquid surfactants i.e., Tween 20 and Labrasol
- Formulation B The waxy materials are melted in a suitable mixing vessel and all other ingredients are mixed in the melted wax. The mixture is sprayed into a spray-congealer or fluid bed processor to solidify the beadlets.
- Formulation C The hot-melt method is performed in a fluid bed. Solid ingredients including the active ingredient, lactose, SLS, and citric acid, are placed in a fluid bed. The melted waxes with liquid surfactant are then sprayed onto the solid ingredients in the fluid bed to form granules.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT98948383T ATE286721T1 (en) | 1997-09-19 | 1998-09-18 | SOLID SOLUTION BEADS |
DE69828635T DE69828635T2 (en) | 1997-09-19 | 1998-09-18 | SOLID SOLUTION BEADS |
JP2000511488A JP2002522354A (en) | 1997-09-19 | 1998-09-18 | Solid solution beadlets |
EP98948383A EP1028712B1 (en) | 1997-09-19 | 1998-09-18 | Solid solution beadlet |
AU94967/98A AU9496798A (en) | 1997-09-19 | 1998-09-18 | Solid solution beadlet |
CA002302275A CA2302275C (en) | 1997-09-19 | 1998-09-18 | Solid solution beadlet |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5940897P | 1997-09-19 | 1997-09-19 | |
US60/059,408 | 1997-09-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999013864A2 true WO1999013864A2 (en) | 1999-03-25 |
WO1999013864A3 WO1999013864A3 (en) | 1999-08-12 |
Family
ID=22022768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/019658 WO1999013864A2 (en) | 1997-09-19 | 1998-09-18 | Solid solution beadlet |
Country Status (9)
Country | Link |
---|---|
US (1) | US6692767B2 (en) |
EP (1) | EP1028712B1 (en) |
JP (1) | JP2002522354A (en) |
AT (1) | ATE286721T1 (en) |
AU (1) | AU9496798A (en) |
CA (1) | CA2302275C (en) |
DE (1) | DE69828635T2 (en) |
ES (1) | ES2236943T3 (en) |
WO (1) | WO1999013864A2 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999056733A1 (en) * | 1998-04-30 | 1999-11-11 | Pharmatec International S.R.L. | Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation |
WO2000009639A2 (en) * | 1998-08-12 | 2000-02-24 | Fuisz Technologies Ltd. | Fatty ester combinations |
JP2003523981A (en) * | 2000-02-24 | 2003-08-12 | セラベル・ファーマスーティカルズ・リミテッド | A new crude drug formulation for oral administration with extended release time of molsidomine |
WO2004084856A2 (en) * | 2003-03-24 | 2004-10-07 | Oralance Pharma | Novel galenical system for active transport, method for preparation and use |
EP1592760A2 (en) * | 2003-01-31 | 2005-11-09 | Smithkline Beecham Corporation | Solid dispersion compositions |
WO2006021455A1 (en) | 2004-08-27 | 2006-03-02 | Novartis Ag | Fast release composition including melt granules of a moisture sensitive drug and process for manufacturing thereof |
EP1729812A1 (en) | 2004-02-27 | 2006-12-13 | Niche Generics Limited | Stable pharmaceutical composition comprising an ace inhibitor |
US7217431B2 (en) | 2001-07-06 | 2007-05-15 | Lifecycle Pharma A/S | Controlled agglomeration |
EP2216015A1 (en) * | 2007-11-02 | 2010-08-11 | Aspion Co., Ltd. | Poorly soluble substance-surfactant complex product, and process for production thereof |
US7943375B2 (en) | 1998-12-31 | 2011-05-17 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
US8133494B2 (en) | 2001-07-05 | 2012-03-13 | Novartis Vaccine & Diagnostics Inc | Expression cassettes endcoding HIV-1 south african subtype C modified ENV proteins with deletions in V1 and V2 |
WO2014047005A1 (en) * | 2012-09-18 | 2014-03-27 | Mcneil-Ppc, Inc. | Sustained release oral dosage forms comprising low melting propionic acid derivative particles |
WO2014047007A1 (en) * | 2012-09-18 | 2014-03-27 | Mcneil-Ppc, Inc. | Suspension pharmaceutical formulations comprising low melting propionic acid derivative particles |
US9539302B2 (en) | 2009-06-18 | 2017-01-10 | Allergan, Inc. | Safe desmopressin administration |
EP2305742B1 (en) * | 2009-10-01 | 2017-02-22 | Symrise AG | Spherical core-shell-particle |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7364752B1 (en) | 1999-11-12 | 2008-04-29 | Abbott Laboratories | Solid dispersion pharamaceutical formulations |
ATE329579T1 (en) * | 1999-11-12 | 2006-07-15 | Abbott Lab | SOLID DISPERSION WITH RITONAVIR, FENOFIBRATE OR GRISEOFULVIN |
EP1267879A2 (en) * | 2000-03-30 | 2003-01-02 | Bristol-Myers Squibb Company | Sustained release beadlets containing stavudine |
DE10026698A1 (en) * | 2000-05-30 | 2001-12-06 | Basf Ag | Self-emulsifying active ingredient formulation and use of this formulation |
WO2002089835A2 (en) * | 2001-05-03 | 2002-11-14 | F. Hoffmann-La Roche Ag | Pharmaceutical dosage form of amorphous nelfinavir mesylate |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
FR2830447B1 (en) * | 2001-10-09 | 2004-04-16 | Flamel Tech Sa | MICROPARTICULAR ORAL GALENIC FORM FOR DELAYED AND CONTROLLED RELEASE OF PHARMACEUTICAL ACTIVE INGREDIENTS |
IL164221A0 (en) * | 2002-04-09 | 2005-12-18 | Flamel Tech Sa | Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillim |
IL164222A0 (en) | 2002-04-09 | 2005-12-18 | Flamel Tech Sa | Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
US8557291B2 (en) | 2002-07-05 | 2013-10-15 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
US8840928B2 (en) * | 2002-07-05 | 2014-09-23 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
CA2491572C (en) * | 2002-07-05 | 2010-03-23 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
US10004729B2 (en) | 2002-07-05 | 2018-06-26 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
US7988993B2 (en) | 2002-12-09 | 2011-08-02 | Andrx Pharmaceuticals, Inc. | Oral controlled release dosage form |
CA2535156A1 (en) | 2003-08-08 | 2005-02-24 | Abgenix, Inc. | Antibodies directed to parathyroid hormone (pth) and uses thereof |
US7318925B2 (en) * | 2003-08-08 | 2008-01-15 | Amgen Fremont, Inc. | Methods of use for antibodies against parathyroid hormone |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8377952B2 (en) * | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
AU2004294813A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride |
WO2005053652A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
WO2005053639A2 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Controlled release multiparticulates formed with dissolution enhancers |
JP2007513147A (en) * | 2003-12-04 | 2007-05-24 | ファイザー・プロダクツ・インク | Spray congealing process for producing a multiparticulate crystalline pharmaceutical composition, preferably containing poloxamer and glyceride, using an extruder |
CA2547597A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate compositions with improved stability |
CA2547774A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Method for making pharmaceutical multiparticulates |
US6984403B2 (en) * | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
EP1694304A2 (en) * | 2003-12-04 | 2006-08-30 | Pfizer Products Inc. | Azithromycin multiparticulate dosage forms by liquid-based processes |
ITMI20032399A1 (en) * | 2003-12-09 | 2005-06-10 | Zambon Spa | PHARMACEUTICAL COMPOSITION CONTAINING GABAPENTIN. |
WO2005079752A2 (en) * | 2004-02-11 | 2005-09-01 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
EP3326617A1 (en) | 2004-06-12 | 2018-05-30 | Collegium Pharmaceutical, Inc. | Abuse-deterrent drug formulations |
WO2006124047A2 (en) * | 2004-08-13 | 2006-11-23 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
ES2662868T3 (en) * | 2004-09-24 | 2018-04-10 | University Of Maryland, Baltimore | Procedure for the treatment of poisoning by an organophosphorus substance |
US9132135B2 (en) * | 2004-09-24 | 2015-09-15 | University Of Maryland, Baltimore | Method of treating organophosphorous poisoning |
FR2886150B1 (en) * | 2005-05-24 | 2007-08-24 | Flamel Technologies Sa | ORAL PHARMACEUTICAL FORM BASED ON AT LEAST ONE ACTIVE INGREDIENT WHOSE SOLUBILITY VARIES IN ACCORDANCE WITH THE CONDITIONS OF GASTRIC PH |
US20100120723A1 (en) * | 2006-12-20 | 2010-05-13 | Mostafa Akbarieh | Pharmaceutical composition comprising a hot-melt granulated lubricant |
US8974801B2 (en) * | 2006-12-21 | 2015-03-10 | Amphastar Pharmaceuticals Inc. | Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate |
FR2913884A1 (en) * | 2007-03-21 | 2008-09-26 | Oralance Pharma Sa | NON-IONIZABLE HYDROPHOBIC GALENIC SYSTEM |
EP2217090A1 (en) * | 2007-12-05 | 2010-08-18 | DSM IP Assets B.V. | Pulverous formulation of a fat-soluble active ingredient |
WO2009153654A1 (en) * | 2008-06-17 | 2009-12-23 | Aurobindo Pharma Limited | Solid dosage forms of antiretrovirals |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
BRPI0906820A2 (en) * | 2009-12-21 | 2013-07-30 | Inst Presbiteriano Mackenzie | ceramic matrix for incorporating controlled release drugs, tablet, method for obtaining the ceramic matrix and method for producing a tablet |
US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US8895537B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating cardiovascular diseases |
US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
US10695431B2 (en) * | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US10695432B2 (en) * | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
PE20191242A1 (en) | 2011-10-25 | 2019-09-16 | Prothena Biosciences Ltd | ANTIBODY FORMULATIONS AND METHODS |
EP2887935A1 (en) * | 2012-08-22 | 2015-07-01 | XenoPort, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
US9675585B1 (en) | 2016-03-24 | 2017-06-13 | Ezra Pharma | Extended release pharmaceutical formulations |
US9687475B1 (en) | 2016-03-24 | 2017-06-27 | Ezra Pharma Llc | Extended release pharmaceutical formulations with controlled impurity levels |
CA3062764A1 (en) * | 2016-04-28 | 2017-11-02 | Amplipharm Pharmaceuticals, LLC | Temozolomide powder formulation |
US9949967B2 (en) * | 2016-04-28 | 2018-04-24 | Amplipharm Pharmaceuticals, LLC | Temozolomide powder formulation |
US10285987B2 (en) | 2017-04-28 | 2019-05-14 | Amplipharm Pharmaceuticals, LLC | Device and kit for dosing and dispensing non-liquid medicine |
WO2017222575A1 (en) | 2016-06-23 | 2017-12-28 | Collegium Pharmaceutical, Inc. | Process of making more stable abuse-deterrent oral formulations |
IT202000022126A1 (en) * | 2020-09-18 | 2022-03-18 | Nutrilinea S R L | PROCESS FOR PREPARING SOLID FORMULATIONS COMPRISING A HYDROPHOBIC COMPOUND DISPERSIBLE IN A COLD LIQUID AND RELATED SOLID FORMULATIONS |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991007171A1 (en) * | 1989-11-13 | 1991-05-30 | Nova Pharmaceutical Corporation | Lipospheres for controlled delivery of substances |
EP0448930A1 (en) * | 1990-03-30 | 1991-10-02 | American Cyanamid Company | Stable compositions for parenteral administration and method of making same |
WO1994012180A1 (en) * | 1992-11-27 | 1994-06-09 | Smithkline Beecham Plc | Cimetidine granules coated with a partially hydrogenated vegetable oil |
WO1994027557A2 (en) * | 1993-05-29 | 1994-12-08 | Smithkline Beecham Corporation | Pharmaceutical thermal infusion process |
WO1995025505A1 (en) * | 1994-03-18 | 1995-09-28 | Pharmavene, Inc. | Hydrophobic drug delivery systems |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3857933A (en) * | 1969-10-17 | 1974-12-31 | Hoechst Ag | Process for the manufacture of a drug dosage form permitting controlled release of active ingredient |
DE3421468A1 (en) * | 1984-06-08 | 1985-12-19 | Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim | LIPID NANOPELLETS AS A CARRIER SYSTEM FOR MEDICINAL PRODUCTS FOR PERORAL USE |
IE904098A1 (en) | 1989-11-13 | 1991-05-22 | Nova Pharm Corp | Lipospheres for controlled delivery of substances |
SE9200858L (en) * | 1992-03-20 | 1993-09-21 | Kabi Pharmacia Ab | Method for producing delayed release pellets |
BE1009257A3 (en) * | 1995-03-21 | 1997-01-07 | Universiteit Gent Lab Voor Far | Pharmaceutical matrix. |
-
1998
- 1998-09-18 WO PCT/US1998/019658 patent/WO1999013864A2/en active IP Right Grant
- 1998-09-18 EP EP98948383A patent/EP1028712B1/en not_active Expired - Lifetime
- 1998-09-18 US US09/156,464 patent/US6692767B2/en not_active Expired - Fee Related
- 1998-09-18 ES ES98948383T patent/ES2236943T3/en not_active Expired - Lifetime
- 1998-09-18 AU AU94967/98A patent/AU9496798A/en not_active Abandoned
- 1998-09-18 JP JP2000511488A patent/JP2002522354A/en active Pending
- 1998-09-18 CA CA002302275A patent/CA2302275C/en not_active Expired - Fee Related
- 1998-09-18 DE DE69828635T patent/DE69828635T2/en not_active Expired - Lifetime
- 1998-09-18 AT AT98948383T patent/ATE286721T1/en not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991007171A1 (en) * | 1989-11-13 | 1991-05-30 | Nova Pharmaceutical Corporation | Lipospheres for controlled delivery of substances |
EP0448930A1 (en) * | 1990-03-30 | 1991-10-02 | American Cyanamid Company | Stable compositions for parenteral administration and method of making same |
WO1994012180A1 (en) * | 1992-11-27 | 1994-06-09 | Smithkline Beecham Plc | Cimetidine granules coated with a partially hydrogenated vegetable oil |
WO1994027557A2 (en) * | 1993-05-29 | 1994-12-08 | Smithkline Beecham Corporation | Pharmaceutical thermal infusion process |
WO1995025505A1 (en) * | 1994-03-18 | 1995-09-28 | Pharmavene, Inc. | Hydrophobic drug delivery systems |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999056733A1 (en) * | 1998-04-30 | 1999-11-11 | Pharmatec International S.R.L. | Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation |
US6551619B1 (en) | 1998-04-30 | 2003-04-22 | Pharmatec International S.R.L. | Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation |
WO2000009639A2 (en) * | 1998-08-12 | 2000-02-24 | Fuisz Technologies Ltd. | Fatty ester combinations |
WO2000009639A3 (en) * | 1998-08-12 | 2002-09-19 | Fuisz Technologies Ltd | Fatty ester combinations |
US7943375B2 (en) | 1998-12-31 | 2011-05-17 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
JP2003523981A (en) * | 2000-02-24 | 2003-08-12 | セラベル・ファーマスーティカルズ・リミテッド | A new crude drug formulation for oral administration with extended release time of molsidomine |
JP4945043B2 (en) * | 2000-02-24 | 2012-06-06 | セラベル・ファーマスーティカルズ・リミテッド | A novel herbal preparation for oral administration with extended release time of molsidomine |
US8133494B2 (en) | 2001-07-05 | 2012-03-13 | Novartis Vaccine & Diagnostics Inc | Expression cassettes endcoding HIV-1 south african subtype C modified ENV proteins with deletions in V1 and V2 |
US9295653B2 (en) | 2001-07-06 | 2016-03-29 | Veloxis Pharmaceuticals A/S | Controlled agglomeration |
US8535799B2 (en) * | 2001-07-06 | 2013-09-17 | Veloxis Pharmaceuticals A/S | Controlled agglomeration |
US7217431B2 (en) | 2001-07-06 | 2007-05-15 | Lifecycle Pharma A/S | Controlled agglomeration |
EP1592760A4 (en) * | 2003-01-31 | 2009-08-12 | Smithkline Beecham Corp | Solid dispersion compositions |
EP1592760A2 (en) * | 2003-01-31 | 2005-11-09 | Smithkline Beecham Corporation | Solid dispersion compositions |
US8911788B2 (en) | 2003-03-24 | 2014-12-16 | Capsugel France SAS | Galenical system for active transport, method for preparation and use |
WO2004084856A2 (en) * | 2003-03-24 | 2004-10-07 | Oralance Pharma | Novel galenical system for active transport, method for preparation and use |
WO2004084856A3 (en) * | 2003-03-24 | 2004-11-25 | Oralance Pharma | Novel galenical system for active transport, method for preparation and use |
EP1729812A1 (en) | 2004-02-27 | 2006-12-13 | Niche Generics Limited | Stable pharmaceutical composition comprising an ace inhibitor |
JP2008510764A (en) * | 2004-08-27 | 2008-04-10 | ノバルティス アクチエンゲゼルシャフト | Immediate release composition comprising molten granules of moisture sensitive drug and process for producing the same |
WO2006021455A1 (en) | 2004-08-27 | 2006-03-02 | Novartis Ag | Fast release composition including melt granules of a moisture sensitive drug and process for manufacturing thereof |
EP2216015A4 (en) * | 2007-11-02 | 2012-12-19 | So Pharmaceutical Corp | Poorly soluble substance-surfactant complex product, and process for production thereof |
EP2216015A1 (en) * | 2007-11-02 | 2010-08-11 | Aspion Co., Ltd. | Poorly soluble substance-surfactant complex product, and process for production thereof |
US9539302B2 (en) | 2009-06-18 | 2017-01-10 | Allergan, Inc. | Safe desmopressin administration |
US11419914B2 (en) | 2009-06-18 | 2022-08-23 | Serenity Pharmaceuticals Llc | Safe desmopressin administration |
EP2305742B1 (en) * | 2009-10-01 | 2017-02-22 | Symrise AG | Spherical core-shell-particle |
WO2014047007A1 (en) * | 2012-09-18 | 2014-03-27 | Mcneil-Ppc, Inc. | Suspension pharmaceutical formulations comprising low melting propionic acid derivative particles |
WO2014047005A1 (en) * | 2012-09-18 | 2014-03-27 | Mcneil-Ppc, Inc. | Sustained release oral dosage forms comprising low melting propionic acid derivative particles |
CN104640571A (en) * | 2012-09-18 | 2015-05-20 | 麦克内尔-Ppc股份有限公司 | Sustained release oral dosage forms comprising low melting propionic acid derivative particles |
Also Published As
Publication number | Publication date |
---|---|
DE69828635T2 (en) | 2005-06-16 |
EP1028712A2 (en) | 2000-08-23 |
US6692767B2 (en) | 2004-02-17 |
CA2302275A1 (en) | 1999-03-25 |
JP2002522354A (en) | 2002-07-23 |
US20010006650A1 (en) | 2001-07-05 |
EP1028712B1 (en) | 2005-01-12 |
DE69828635D1 (en) | 2005-02-17 |
CA2302275C (en) | 2009-12-08 |
ES2236943T3 (en) | 2005-07-16 |
ATE286721T1 (en) | 2005-01-15 |
AU9496798A (en) | 1999-04-05 |
WO1999013864A3 (en) | 1999-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1028712B1 (en) | Solid solution beadlet | |
US8734849B2 (en) | Multiparticle pharmaceutical dosage form containing a mucoadhesively formulated peptide or protein active substances method for producing said pharmaceutical dosage form | |
KR0148002B1 (en) | Sustained release preparation | |
AU698360B2 (en) | Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application | |
US5403593A (en) | Melt granulated compositions for preparing sustained release dosage forms | |
EP0368247B1 (en) | Controlled release preparations | |
KR100336090B1 (en) | Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixture thereof | |
FI94094C (en) | Carrier composition for delayed action drug preparations | |
JP2005506323A (en) | Functional powder for oral delivery | |
CA2063141C (en) | Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets | |
IE902823A1 (en) | Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets | |
MX2007000955A (en) | Multiparticle pharmaceutical dosage form for a low-soluble active substances and method for producing said pharmaceutical dosage form. | |
JP2001278813A (en) | Oral administration form having delayed active substance release and high mechanical stability, medicine having the same administration form and use of such administration form | |
TW585770B (en) | Gastric and/or duodenal adhestive pharmaceutical composition | |
US5739165A (en) | Stabilized solid pharmaceutical preparation and method of producing the same | |
WO2000074656A1 (en) | Microencapsulated and controlled-release herbal formulations | |
CN1261273A (en) | Delayed-release dosage forms of sertraline | |
AU2002300572B2 (en) | Solid Solution Beadlet | |
US20030157174A1 (en) | Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component | |
JP4840793B2 (en) | Enteric granule preparation of poorly water-soluble drug characterized by blending water-repellent ingredients | |
JP2760012B2 (en) | Sustained fine granules | |
JP2729494B2 (en) | Stable fine granules | |
MXPA06000430A (en) | Multiparticle pharmaceutical dosage form containing a mucoadhesively formulated peptide or protein active substances method for producing said pharmaceutical dosage form | |
CZ20002675A3 (en) | Extended release tiagabine formulations with reduced side effects |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP MX |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP MX |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
ENP | Entry into the national phase |
Ref document number: 2302275 Country of ref document: CA Ref country code: CA Ref document number: 2302275 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998948383 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 511488 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 94967/98 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1998948383 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998948383 Country of ref document: EP |